Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of Heritage Commerce Corp to CVB Financial Corp, specifically whether the exchange of 0.6500 shares of CVB common stock for each Heritage share is equitable for Heritage shareholders [1]. Group 1: Investigation Details - The investigation focuses on potential violations of federal securities laws and breaches of fiduciary duties by Heritage and its board, including failure to secure the best possible consideration for shareholders [2]. - Concerns include whether CVB is underpaying for Heritage and whether all material information necessary for shareholders to assess the merger consideration has been disclosed [2]. Group 2: Legal Actions - Halper Sadeh LLC may seek increased consideration for Heritage shareholders, additional disclosures, and other forms of relief related to the proposed transaction [3]. - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased CarMax, Inc. securities between June 20, 2025, and November 5, 2025, of the January 2, 2026, deadline to become lead plaintiffs in a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought CarMax securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiffs must act by January 2, 2026 [3]. - The lawsuit alleges that defendants made materially false and misleading statements regarding CarMax's growth prospects, which were overstated due to temporary market conditions [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Avantor, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class period for the Avantor common stock lawsuit is from March 5, 2024, to October 28, 2025, inclusive [1] - Investors who purchased Avantor common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3] Group 3: Case Allegations - The lawsuit alleges that Avantor's competitive positioning was misrepresented, indicating it was weaker than publicly stated [4] - It claims that Avantor faced negative impacts from increased competition, leading to materially false and misleading representations about its business and prospects [4] - The lawsuit asserts that when the true details became known, investors suffered damages [4]

Core Viewpoint - Rezolute, Inc. has faced significant stock price decline of over 85% following the failure of its Phase 3 sunRIZE study in congenital hyperinsulinism, leading to an investigation by Block & Leviton for potential securities law violations [2][4]. Group 1: Company Performance - Shares of Rezolute fell over 85% on December 11 after the company announced that its Phase 3 sunRIZE study failed to meet its primary or key secondary endpoints [2]. - The company had previously made optimistic statements about the strength of earlier data and the outlook for the program, which may have misled investors [2]. Group 2: Legal Investigation - Block & Leviton is investigating whether Rezolute, Inc. committed securities law violations and may file an action to recover losses on behalf of affected investors [4]. - Investors who have lost money in their Rezolute investment are encouraged to contact Block & Leviton for potential recovery options [3][5]. Group 3: Whistleblower Information - Individuals with non-public information about Rezolute, Inc. are encouraged to assist in the investigation or file a report with the Securities Exchange Commission under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Group 4: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors and representing many of the nation's top institutional investors [7].

New York, New York--(Newsfile Corp. - December 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE: ARE) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Alexandria Real Estate, you are encouraged to obtain additional information by visiting: https:/ ...

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. and its senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Eastern District of Virginia, titled MacMahon v. Stride, Inc., et al., No. 1:25-cv-02019, and investors have until January 12, 2026, to seek lead plaintiff status [3]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Stride securities [3]. Group 2: Allegations Against Stride - Stride, an education technology company, is accused of inflating enrollment numbers by retaining "ghost students," neglecting compliance requirements, and providing a poor customer experience, leading to higher withdrawal rates and lower conversion rates [4]. - The company claimed to be experiencing growth and strong demand, which is now alleged to be misleading [4]. Group 3: Stock Performance Impact - On September 14, 2025, a report of the lawsuit caused Stride's stock to drop by $18.60 per share, over 11%, from $158.36 to $139.76 [5]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48 per share, more than 54%, from $153.53 to $70.05, with an estimated impact of 10,000-15,000 fewer enrollments [6].

New York, New York--(Newsfile Corp. - December 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ ...

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Synopsys, Inc. provides design automation software products used for designing and testing integrated circuits. Its Design IP segment, which supplies pre-designed silicon components to semiconductor companies, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Allegations and Financial Performance - The lawsuit claims that Synopsys misled investors by stating that customers relied on its IP to minimize integration risk and that the company was experiencing strength in Europe and South Korea. However, it is alleged that customers began requiring more customization for IP components, negatively impacting the economics of the Design IP business and jeopardizing the business model [5]. - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% year-over-year decline, and a net income of $242.5 million, which is a 43% year-over-year decline. The company indicated that increased customization demands from customers were leading to longer timelines and more resource requirements, prompting discussions about changing its business model [6]. Stock Market Reaction - Following the release of disappointing Q3 2025 financial results, Synopsys's stock price fell from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025, marking a nearly 36% decline [6].

New York, New York--(Newsfile Corp. - December 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in CarMax, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/carmax-inc-class-ac ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].